Choose Your language:
- Testimonials
-
great service thanks
- andrew
Read more »
Our billing is certified by:
- News
-
- FDA approved Tadalafil medication for the treatment of erectile dysfunction accompanied with primary and secondary symptoms of benign prostatic hyperplasia (BPH) in men above 45 years.
- Considering the information of three randomized, multicenter, double, blind clinical studies and a retrospective analysis of the medical documentation, FDA approved on October 7, 2011 Tadalafil medication for the treatment of erectile dysfunction accompanied with primary and secondary symptoms of benign prostatic hyperplasia (BPH) in men above 45 years
- The forming, development and monitoring of the pharmaceutical market in USA in September 2011
- In spite of low rates and stagnation of industrial development, the pharmaceutical market shows a dynamical growth
- Sildenafil citrate and pulmonary arterial hypertension
- Pulmonary arterial hypertension Definition “pulmonary arterial hypertension” is related to a group of diseases characterized by: - Progressive increase in pulmonary vascular resistance; - Reduction in pulmonary bloodflow; - High pulmonary artery pressure; - Contractility of the heart right ventricle; - Right ventricular failure
- Fruit and vegetables do not reduce overall cancer risk, review concludes
- Eating lots of fruit and vegetables will do little to reduce your risk of developing cancer, according to a review of a decade of research involving more than a million people
- Common painkillers could be linked to male reproductive disorder
- The use of mild painkillers, such as paracetamol, in pregnancy – previously considered harmless to the baby in the womb – could be a major factor in the rise of male reproductive disorders, according to a study
-
- Merck Wins U.S. ZETIA(R) (ezetimibe)/ VYTORIN(R) (ezetimibe/simvastatin ... - MarketWatch (press release)
- Merck Wins U
- Merck wins patent fight on Zetia, Vytorin; Fitch warns of 'pure pharma' risks; - FiercePharma
- Merck wins patent fight on Zetia, Vytorin; Fitch warns of 'pure pharma' risks;FiercePharmaArticle | Follow @FiercePharma > A US court upheld Merck's ($MRK) patent on the active ingredient ezetimibe, marketed as the cholesterol-lowering Zetia and in the combo cholesterol pill Vytorin
- Investor Medical Waves - (VVUS, MRK, MYL, AMPE) - Galaxy Stocks
- Investor Medical Waves - (VVUS, MRK, MYL, AMPE)Galaxy StocksInc
- Advanced Atherosclerosis: The Heart and Beyond - Medscape
- Advanced Atherosclerosis: The Heart and BeyondMedscapeThe premise of AIM-HIGH was to see if adding extended-release niacin to raise HDL cholesterol in patients who had already achieved a very low LDL cholesterol level (40 to 80 mg/dL) with simvastatin (and ezetimibe if needed) would lead to further risk
- Toward Regenerative Medicine Against Atherosclerosis cardiovascular disease - Next Big Future
- Toward Regenerative Medicine Against Atherosclerosis cardiovascular diseaseNext Big FutureOnce-promizing agents such as ezetimibe, niacin, ApoA-1 Milano, and torcetrapib have either been found to provide no benefit, or evento increase mortality rates
